ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,221.42
-0.02%
US Tech 100
17,731.20
0.05%
다우존스 지수
39,431.51
-0.21%
Bitcoin
61,837.10
-1.70%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 영국
  5. LSE
  6. Johnson & Johnson (0R34)

  7. Johnson & Johnson (0R34) 뉴스

0R34

Johnson & Johnson (0R34)

Johnson & Johnson
일자:
정렬 기준:
 검색 관련기사 보기:LSE:0R34
일자시간출처헤드라인심볼기업
2024/05/0122:17Alliance NewsAlliance NewsTOP NEWS: J&J proposes USD6.48 billion settlement of cancer lawsuitsLSE:0R34Johnson & Johnson
2024/04/1619:54Alliance NewsAlliance NewsTOP NEWS: Johnson & Johnson upgrades guidance on swing to earningsLSE:0R34Johnson & Johnson
2024/04/0520:02Alliance NewsAlliance NewsTOP NEWS: J&J swoops for Shockwave Medical in USD13.1 billion dealLSE:0R34Johnson & Johnson
2024/03/2603:28Alliance NewsAlliance NewsIN BRIEF: J&J submits US premarket approval application for VaripulseLSE:0R34Johnson & Johnson
2024/03/1820:10Alliance NewsAlliance NewsIN BRIEF: Johnson & Johnson receives FDA recommendation for CarvyktiLSE:0R34Johnson & Johnson
2024/02/2403:32Alliance NewsAlliance NewsIN BRIEF: Johnson & Johnson gets EMA nod for Carvykti in myelomaLSE:0R34Johnson & Johnson
2024/02/0215:22Alliance NewsAlliance NewsTOP NEWS: US sends drugmakers initial offers in Medicare price talksLSE:0R34Johnson & Johnson
2024/01/2320:41Alliance NewsAlliance NewsTOP NEWS: Johnson & Johnson eyes future growth; 2023 sales riseLSE:0R34Johnson & Johnson
2024/01/2006:34Alliance NewsAlliance NewsIN BRIEF: J&J gets US FDA approval for cancer treatment BalversaLSE:0R34Johnson & Johnson
2023/12/0522:24Alliance NewsAlliance NewsTOP NEWS: J&J expects strong long-term growth in three key driversLSE:0R34Johnson & Johnson
2023/10/2320:03Alliance NewsAlliance NewsJ&J report slew of positive trial results focused on various cancersLSE:0R34Johnson & Johnson
2023/10/1719:46Alliance NewsAlliance NewsTOP NEWS: J&J raises full-year sales outlook after "solid" quarterLSE:0R34Johnson & Johnson
2023/10/0700:52Alliance NewsAlliance NewsIN BRIEF: J&J applies for indication extension to EMA for RybrevantLSE:0R34Johnson & Johnson
2023/10/0401:00Alliance NewsAlliance NewsDrugmakers agree to US government price talks amid pushbackLSE:0R34Johnson & Johnson
2023/09/0714:50Alliance NewsAlliance NewsJ&J's Janssen ends Phase 3 MACiTEPH study evaluating macitentanLSE:0R34Johnson & Johnson
2023/08/3101:07Alliance NewsAlliance NewsTOP NEWS: J&J forecasts strong growth in earnings after Kenvue splitLSE:0R34Johnson & Johnson
2023/08/1105:34Alliance NewsAlliance NewsIN BRIEF: Johnson & Johnson's blood cancer therapy approved by FDALSE:0R34Johnson & Johnson
2023/07/2020:30Alliance NewsAlliance NewsTOP NEWS: J&J ups full-year guidance after "robust" second quarterLSE:0R34Johnson & Johnson
2023/05/3100:48Alliance NewsAlliance NewsJ&J seeks FDA approval for pulmonary arterial hypertension treatmentLSE:0R34Johnson & Johnson
2023/05/1004:23Alliance NewsAlliance NewsJ&J says Tremfya data shows positive results for ulcerative colitisLSE:0R34Johnson & Johnson
2023/05/0420:41Alliance NewsAlliance NewsIN BRIEF: J&J prices subsidiary Kenvue's NYSE initial public offeringLSE:0R34Johnson & Johnson
2023/05/0115:51Alliance NewsAlliance NewsJohnson & Johnson reports first results from TAR-200 studyLSE:0R34Johnson & Johnson
2023/04/1820:06Alliance NewsAlliance NewsTOP NEWS: J&J swings to first quarter loss due to litigation costsLSE:0R34Johnson & Johnson
2023/04/0514:01Alliance NewsAlliance NewsJ&J proposes USD8.9 billion settlement of talc cancer claimsLSE:0R34Johnson & Johnson
2023/04/0505:57Alliance NewsAlliance NewsIN BRIEF: J&J subsidiary re-files for bankruptcy amid talc claimsLSE:0R34Johnson & Johnson
2023/03/1803:04Alliance NewsAlliance NewsIN BRIEF: Johnson & Johnson notes positive data for psoriasis drugLSE:0R34Johnson & Johnson
2023/01/2421:33Alliance NewsAlliance NewsTOP NEWS: J&J fourth-quarter revenue falls on fewer Covid jab salesLSE:0R34Johnson & Johnson
2023/01/0518:06Alliance NewsAlliance NewsJohnson & Johnson's consumer health unit files to go publicLSE:0R34Johnson & Johnson
2022/12/1001:51Alliance NewsAlliance NewsIN BRIEF: Johnson & Johnson submits licence application to FDALSE:0R34Johnson & Johnson
2022/12/0120:37Alliance NewsAlliance NewsJohnson & Johnson appoints Chief Executive Joaquin Duato as new chairLSE:0R34Johnson & Johnson
 검색 관련기사 보기:LSE:0R34

최근 히스토리

EU
10X0Z
10X0Z
BIT
UB26GT
UniCredit Bank
Delayed Upgrade Clock
ADVFN Logo

대한민국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유